Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news